Research progress of nuclear factor erythroid 2-related factor 2 in pulmonary fibrosis
10.12092/j.issn.1009-2501.2023.09.014
- Author:
Jie WANG
1
;
Feng CHEN
1
;
Shengfei LIU
1
;
Long LI
2
Author Information
1. The First Clinical Medical College of Lanzhou University
2. Department of Respiratory Medicine, the First Hospital of Lanzhou University
- Publication Type:Journal Article
- Keywords:
autophagy;
epithelial-mesenchymal transition;
ferroptosis;
nuclear factor erythroid 2-related factor 2
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(9):1067-1072
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary fibrosis is a common chronic interstitial lung disease. It is characterized by excessive deposition of extracellular matrix and remodeling of lung tissue structure, resulting in severe impairment of lung function. The cause of its pathogenesis is still unclear. Therefore, it is urgent to explore its pathogenesis and find new targets to combat pulmonary fibrosis. Studies have shown that nuclear factor erythroid 2-related factor 2 can maintain the body's redox homeostasis by regulating antioxidant genes and combining antioxidant response components, thereby protecting tissues and cells from oxidative stress. In recent years, many studies have proved that nuclear factor erythroid 2 -related factor 2 can play an anti-fibrotic role by alleviating oxidative stress, inhibiting macrophage polarization, activating autophagy, inhibiting ferroptosis, and blocking epithelial-mesenchymal transition. This paper provides a brief review of the association and research progress of nuclear factor erythroid 2-related factor 2 with pulmonary fibrosis, with the aim of providing a new direction for the precise treatment of pulmonary fibrosis.
